The effect of renal replacement therapy on the concentration of tigecycline in the blood in patients with sepsis-associated acute kidney injury

The objective was to evaluate the effect of renal replacement therapy on the concentration of tigecycline in the blood in the treatment of patients with sepsis and acute kidney injury.

Materials and methods. The serum level of tigecycline was analyzed in three patients with sepsis-associated acute kidney injury against the back -ground of renal replacement therapy (RRT) in the hemodiafiltration mode. The quantitative content of tigecycline was determined by high-performance liquid chromatography.

Results. Significant variability of serum tigecycline levels was revealed in patients with sepsis-associated acute kidney injury (AKI) under the conditions of the use of RRT. The use of standard dosage regimens of tigecycline in this situation may be accompanied by both a significant increase in the concentration of the drug in the blood relative to the target values, and its low level, which does not reach the values of the minimum inhibitory concentration (MIC) for pathogenic strains.

Conclusion. Significant variability of serum concentrations of tigecycline in patients with sepsis-associated AKI against the background of RRT causes the emergence of potential risks associated with both insufficient safety of treatment due to possible accumulation and  significant excess of the target concentration value against the background of inhibition of the functions of the physiological excretory systems  of the body, so with the low effectiveness of antibacterial therapy in conditions of increasing the rate of elimination of the drug from the  systemic bloodstream due to extracorporeal clearance and reducing the concentration of the antibiotic to subtherapeutic.

1. Kim T.G., Magomedov M.А., Protsenko D.N. et al. The current state of renal replacement therapy in the treatment of sepsis. Messenger of anesthesiology and resuscitation, 2021, vol. 18, no. 4, pp. 80–89. (In Russ.) DOI: 10.21292/2078-5658-2021-18-4-80-89.

2. Marukhov A.V., Murzina E.V., Zakharov M.V. et al. Evaluation of plasma levels of meropenem in septic patients during extracorporeal blood purification. Medical Academic Journal, 2020, vol. 20, no. 4, pp. 81–94. (In Russ.) DOI: 10.17816/MAJ54636.

3. Marukhov A.V., Zakharov M.V., Chubchenko N.V. et al. Antibacterial therapy of sepsis in extracorporeal detoxification: current problems and ways to solve them. Messenger of anesthesiology and resuscitation, 2020, vol. 17, no. 6, pp. 80–87. (In Russ.) DOI: 10.21292/2078-5658-2020-17-6-80-87.

4. Polushin Yu.S., Dreval R.O., Zabotina A.N. Clinical and economic assessment of the therapy of acute kidney injury in sepsis with continuous combined methods of renal replacement therapy. Messenger of anesthesiology and resuscitation, 2021, vol. 18, no. 5, pp. 7–20. (In Russ.) DOI: 10.21292/2078-5658-2021-18-5-7-20.

5. Polushin Yu.S., Sokolov D.V. Kidney dysfunction in critically ill patients. Messenger of anesthesiology and resuscitation, 2018, vol. 15, no. 5, pp. 54–64. (In Russ.) DOI: 10.21292/2078-5658-2018-15-5-54-64.

6. Broeker A., Wicha S. G., Dorn C. et al. Tigecycline in critically ill patients on continuous renal replacement therapy: a population pharmacokinetic study // Crit Care. – 2018. – Vol. 22, № 1. – P. 341. DOI: 10.1186/s13054-018-2278-4.

7. Cutuli S. L., De Pascale G., Lisi L. et al. Tigecycline pharmacokinetics in critically ill patients on renal replacement therapy: possible warnings and potential perspectives for the research agenda // Ann Intensive Care. – 2020. – Vol. 10, № 1. – Р. 141. DOI: 10.1186/s13613-020-00759-4.

8. De Pascale G., Lisi L., Ciotti G. M. et al. Pharmacokinetics of high-dose tigecycline in critically ill patients with severe infections // Ann Intensive Care. – 2020. – Vol. 10, № 1. – P. 94. DOI: 10.1186/s13613-020-00715-2.

9. Gatti M., Pea F. Antimicrobial dose reduction in continuous renal replacement therapy: myth or real need? A practical approach for guiding dose optimization of novel antibiotics // Clin Pharmacokinet. – 2021. – Vol. 60, № 10. – Р. 1271–1289. DOI: 10.1007/s40262-021-01040-y.

10. Honore P. M., David C., Kugener L. et al. No dose adjustment of tigecycline is necessary during continuous renal replacement therapy: we are not sure // Crit Care. – 2020. – Vol. 24, № 1. – Р. 59. DOI: 10.1186/s13054-020-2775-0.

11. Li L., Li X., Xia Y. et al. Recommendation of antimicrobial dosing optimization during continuous renal replacement therapy // Front Pharmacol. – 2020. – № 11. – Р. 786. DOI: 10.3389/fphar.2020.00786.

12. Onichimowski D., Ziolkowski H., Nosek K. et al. Comparison of adsorption of selected antibiotics on the filters in continuous renal replacement therapy circuits: in vitro studies // J Artificial Organs. – 2020. – Vol. 23, № 2. – Р. 163–170. DOI: 10.1007/s10047-019-01139-x.

13. Xu Y., Jin L., Liu N. et al. Evaluation of the ratio of the estimated area under the concentration-time curve to minimum inhibitory concentration (estimated AUIC) as a predictor of the outcome for tigecycline treatment for pneumonia due to multidrug-resistant bacteria in an intensive care unit // Int J Infect Dis. – 2019. – Vol. 82. – Р. 79–85. DOI: 10.1016/j.ijid.2019.03.011.

14. Yaghoubi S., Zekiy A. O., Krutova M. et al. Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review // Eur J Clin Microbiol Infect Dis. – 2022. – Vol. 41, № 7. – Р. 1003–1022. DOI: 10.1007/s10096-020-04121-1.

15. Zhou C. C., Huang F., Zhang J. M. et al. Population pharmacokinetics of tigecycline: a systematic review // Drug Des Devel Ther. – 2022. – Vol. 16. – Р. 1885–1896. DOI: 10.2147/DDDT.S365512